文献速递骨质疏松与代谢性骨病

老年女性抗骨吸收治疗期间钙与蛋白质摄入对骨变化的影响

Dietary and supplemental calcium intake and bone changes during antiresorptive osteoporosis treatment in older women: a longitudinal observational study.
PubMed 文献 · Osteoporos Int · 2026-07-17

该纵向观察研究分析日内瓦退休队列586名钙充足老年女性(中位年龄67岁),发现总钙摄入(中位1503 mg/天)或钙补充剂使用不影响抗骨吸收药物对全髋骨密度和强度的改善,而蛋白质摄入低于0.8 g/kg/天会减弱抗骨吸收药物的疗效。

要点

  • 钙充足老年女性中,钙补充剂对抗骨吸收药物疗效无显著影响。
  • 蛋白质摄入低于0.8 g/kg/天时,抗骨吸收药物改善骨小梁骨密度和全髋强度的效果减弱。
  • 钙摄入充足(≥1200 mg/天)者可能无需常规补充钙剂。

核心结论

  • 在钙充足老年女性中,影响抗骨吸收药物对全髋骨变化效果的是蛋白质摄入而非钙补充剂。
  • 钙摄入充足时常规补钙的必要性受到质疑,充足蛋白质摄入对优化骨质疏松管理很重要。

研究设计与样本

  • 纵向观察研究,分析日内瓦退休队列586名女性(中位年龄67岁)数据。
  • 101人使用绝经激素治疗,67人使用抗骨吸收药物(双膦酸盐、地诺单抗或雷洛昔芬),418人未用骨质疏松药物。
  • 中位随访3.5年,用2D/3D-DXA和有限元分析评估全髋骨密度、强度和结构年变化。
  • 通过食物频率问卷评估钙和蛋白质摄入,基线及随访记录钙补充剂使用。

主要发现

  • 总钙摄入(饮食+补充剂)为1503 mg/天,71%女性达到推荐量(≥1200 mg/天),51%使用钙补充剂,70%使用维生素D。
  • 绝经激素治疗或抗骨吸收药物较未用药增加全髋骨密度和强度。
  • 总钙摄入高于或低于1200 mg/天、以及钙补充剂使用与否,均未显著影响骨结局。
  • 钙摄入低于800 mg/天且未用钙补充剂时,用药与未用药女性的骨密度或骨强度变化无差异。
  • 蛋白质摄入低于0.8 g/kg/天时,抗骨吸收药物效果减弱,骨小梁骨密度改善减少(P=0.009),全髋强度改善减少(P=0.040)。

关键数值与推荐

  • 总钙摄入中位1503 mg/天,71%女性≥1200 mg/天。
  • 蛋白质摄入低于0.8 g/kg/天时,抗骨吸收药物组骨小梁骨密度改善减少(P=0.009),全髋强度改善减少(P=0.040)。

临床怎么用

  • 对钙摄入充足的老年女性,可考虑不常规处方钙补充剂。
  • 处方抗骨吸收药物时应评估并优化蛋白质摄入,避免低于0.8 g/kg/天。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Calcium supplements are often prescribed with osteoporosis medications without considering dietary adequacy. In calcium-replete older women, calcium supplements had little effect on the response to antiresorptives, whereas low protein intake blunted their benefits. Calcium supplementation may be unnecessary when intake is adequate, and nutrition should be optimized for osteoporosis treatment. PURPOSE: Osteoporosis medications (OM) are commonly prescribed with calcium supplements (CaS) without considering dietary adequacy. We investigated whether calcium and protein intakes influence the effect of OM on total hip bone mineral density (BMD) and strength in calcium-replete women. METHODS: Data from 586 women (median age 67 years) from the Geneva Retirees Cohort were analyzed: 101 on menopausal hormone therapy (MHT), 67 on antiresorptives (AR) (bisphosphonates, denosumab or raloxifene), and 418 without OM. Annual changes in total hip BMD, strength, and structure were assessed over a median 3.5 years using 2D/3D-DXA and finite element analysis. Calcium and protein intakes were assessed by food frequency questionnaire; CaS use was recorded at baseline and follow-up. RESULTS: Total calcium intake (diet + supplements) was 1503 mg/day; 71% women met recommendations (≥ 1200 mg/day), 51% used CaS, and 70% vitamin D. MHT or AR increased total hip BMD and strength versus no OM. Neither total calcium intake (above or below 1200 mg/day) nor CaS use significantly affected bone outcomes. However, in women with low calcium intake (< 800 mg/day), no difference in changes of BMD or bone strength was observed between women with and without OM in the absence of CaS. In women with protein intake < 0.8 g/kg/day, AR effects were blunted, with reduced improvements in trabecular BMD (P = 0.009) and total hip strength (P = 0.040). CONCLUSION: In calcium-replete older women, protein intake rather than CaS influences total hip bone changes with OM. These findings question routine CaS in women with adequate calcium intake and emphasize the importance of sufficient protein intake for optimal osteoporosis management. CLINICAL TRIAL REGISTRATION: GERICO http://www.isrctn.com/ISRCTN11865958.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Papageorgiou M, Gugler Y, Ferrari S, et al. Dietary and supplemental calcium intake and bone changes during antiresorptive osteoporosis treatment in older women: a longitudinal observational study. Osteoporos Int. 2026. PMID: 42463975. doi:10.1007/s00198-026-08154-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。